COMMUNICATION

COM-2026-013

APRIL 1, 2026

PharmaNavigator

PharmPix Clinical Department

At PharmPix, we help you navigate your way through informed education.

Orforglipron: The New Oral Small-Molecule GLP-1 Agonist

Orforglipron is an investigational, once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Eli Lilly for the treatment of type 2 diabetes (T2DM) and obesity. Unlike currently available GLP-1 therapies, which are predominantly injectable peptides, orforglipron is a non-peptide small molecule, allowing for oral administration without the strict fasting or water intake requirements seen with oral semaglutide. This distinction may significantly improve patient convenience, adherence, and overall acceptance of GLP-1 therapy.

Clinical trial data from the ACHIEVE program in T2DM demonstrated hemoglobin A1C reductions of approximately 1.3% to 2.2%, along with weight loss of approximately 7.9% to 9.2% (roughly 16–20 pounds), depending on dose. In head-to-head comparisons, orforglipron showed superior glycemic and weight outcomes versus oral semaglutide. In the ATTAIN program evaluating obesity, weight loss reached approximately 10% to 12.4% over 72 weeks, with additional improvements observed in cardiometabolic parameters such as blood pressure and lipid profiles. Data also suggest that orforglipron may help maintain weight loss achieved with prior injectable GLP-1 therapies, with minimal weight regain following transition.

The safety profile of orforglipron appears consistent with the GLP-1 class, with gastrointestinal adverse events such as nausea, vomiting, and diarrhea being the most commonly reported. These events were generally mild to moderate in severity and comparable to other agents in the class.

While its efficacy in weight reduction appears somewhat lower than that of high-potency injectable agents such as tirzepatide and semaglutide, its oral formulation, lack of administration restrictions, and small-molecule manufacturing process could improve scalability and access. These attributes may position orforglipron as an attractive option for patients who are unwilling or unable to use injectable therapies.

Orforglipron has been submitted to the U.S. Food and Drug Administration for obesity, with a regulatory decision anticipated in 2026, and a diabetes indication expected to follow. If approved, it may be positioned as an alternative to injectable GLP-1 therapies, a step therapy option within formulary management strategies, or a maintenance therapy following weight loss achieved with more potent agents.

REFERENCES:

1. Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., Allen, S. E., Ahmad, N. N., & Klise, S. R. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. *New England Journal of Medicine*. https://doi.org/10.1056/nejmoa2511774
2. *Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial | Eli Lilly and Company*. (2024). Eli Lilly and Company. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically
3. PRN (2026, February 26). *Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet*. Prnewswire.com; Cision PR Newswire. https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar-control-and-weight-loss-compared-to-oral-semaglutide-in-head-to-head-type-2-diabetes-trial-published-in-the-lancet-302697632.html
4. *Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine | Eli Lilly and Company*. (2024). Eli Lilly and Company. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight

If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext.219. Our pharmacists will help you. In addition, know that you can access our recent communications at our providers' portal: https://www.pharmpix.com/providers/.